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SCIENTIFIC OPINION 
Scientific Opinion on the substantiation of health claims related to: 
a combination of millet seed extract, L-cystine and pantothenic acid 
(ID 1514), amino acids (ID 1711), carbohydrate and protein combination 
(ID 461), Ribes nigrum L. (ID 2191), Vitis vinifera L. (ID 2157), Grifola 
frondosa (ID 2556), juice concentrate from berries of Vaccinium 
macrocarpon Aiton and Vaccinium vitis-idaea L. (ID 1125, 1288), blueberry 
juice drink and blueberry extracts (ID 1370, 2638), a combination of 
anthocyanins from bilberry and blackcurrant (ID 2796), inulin-type 
fructans (ID 766, 767, 768, 769, 770, 771, 772, 804, 848, 849, 2922, 3092), 
green clay (ID 347, 1952), foods and beverages “low in energy”, 
“energy-free” and “energy-reduced” (ID 1146, 1147), and carbohydrate 
foods and beverages (ID 458, 459, 470, 471, 654, 1277, 1278, 1279) pursuant 
to Article 13(1) of Regulation (EC) No 1924/2006
1
 
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)
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European Food Safety Authority (EFSA), Parma, Italy
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SUMMARY 
Following a request from the European Commission, the Panel on Dietetic Products, Nutrition and 
Allergies was asked to provide a scientific opinion on a list of health claims pursuant to Article 13 of 
Regulation (EC) No 1924/2006. This opinion addresses the scientific substantiation of health claims 
in relation to: a combination of millet seed extract, L-cystine and pantothenic acid, amino acids, 
carbohydrate and protein combination, Ribes nigrum L., Vitis vinifera L., Grifola frondosa, juice 
concentrate from berries of Vaccinium macrocarpon Aiton and Vaccinium vitis-idaea L., blueberry 
juice drink and blueberry extracts, a combination of anthocyanins from bilberry and blackcurrant, 
inulin-type fructans, green clay, foods and beverages ―low in energy‖, ―energy-free‖ and ―energy-
reduced‖, and carbohydrate foods and beverages. The scientific substantiation is based on the 
information provided by the Member States in the consolidated list of Article 13 health claims and 
references that EFSA has received from Member States or directly from stakeholders. 
The foods/food constituents that are the subject of this opinion are: 
 Combination of millet seed extract, L-cystine and pantothenic acid related to the following 
claimed effect: contribution to normal hair growth (ID 1514). 
 Amino acids related to the following claimed effect: skeletal muscle tissue repair and recovery 
following strenuous exercise (ID 1711). 
 Carbohydrate and protein combination related to the following claimed effect: faster skeletal 
muscle recovery after exercise (ID 461). 
 Ribes nigrum L. related to the following claimed effect: maintenance of normal muscles and 
joints (ID 2191). 
 Vitis vinifera L. related to the following claimed effect: maintenance of normal venous blood 
flow (ID 2157). 
 Grifola frondosa related to the following claimed effect: blood glucose control (ID 2556). 
 Juice concentrate from berries of Vaccinium macrocarpon Aiton and Vaccinium vitis-idaea L. 
related to the following claimed effect: defence against bacterial pathogens in the lower urinary 
tract (ID 1125, 1288). 
 Blueberry juice drink and blueberry extracts related to the following claimed effects: 
maintenance of normal vision and improvement of visual adaptation to the dark (ID 1370, 2638). 
 Combination of anthocyanins from bilberry and blackcurrant related to the following claimed 
effect: improvement of visual adaptation to the dark and reduction of ocular discomfort 
(ID 2796). 
 Inulin-type fructans related to the following claimed effects: bowel function, defence against 
gastrointestinal pathogens, increase in calcium absorption and retention, increase in bone mineral 
density, maintenance of normal blood glucose concentrations, and satiety (ID 766, 767, 768, 769, 
770, 771, 772, 804, 848, 849, 2922, 3092).  
                                                                                                                                                                     
 
Meurman and Hildegard Przyrembel. The members of the Claims Sub-Working Group on Weight 
Management/Satiety/Glucose and Insulin Control/Physical Performance: Kees de Graaf, Joanne Harrold, Mette Hansen, 
Mette Kristensen, Anders Sjödin and Inge Tetens. The members of the Claims Sub-Working Group on Mental/Nervous 
System: Jacques Rigo, Astrid Schloerscheidt, Barbara Stewart-Knox, Sean (J.J.) Strain, and Peter Willatts. 
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 Green clay related to the following claimed effects: reduction of gastro-intestinal discomfort (ID 
347, 1952). 
 Foods and beverages ―low in energy‖, ―energy-free‖ and ―energy-reduced‖ related to the 
following claimed effects: body weight management (ID 1146, 1147). 
 Carbohydrate foods and beverages related to the following claimed effects: physical capacity and 
performance in relation to short-term and endurance exercise (including endurance capacity and 
performance during the subsequent exercise bout after strenuous exercise) by contributing to the 
replenishment of muscle and liver glycogen stores, reduction in rated perceived exertion/effort 
during exercise, and recovery from muscle fatigue after exercise (ID 458, 459, 470, 471, 654, 
1277, 1278, 1279). 
The information given in the consolidated list and the references provided did not allow the Panel to 
characterise the foods/food constituents which are the subject of this opinion.  
The Panel considers that the foods/food constituents which are the subject of this opinion are not 
sufficiently characterised, or are not sufficiently characterised in relation to the proposed claimed 
effects. 
On the basis of the data presented, the Panel concludes that a cause and effect relationship cannot be 
established between the foods/food constituents which are the subject of this opinion and the claimed 
effects. 
KEY WORDS 
Foods, constituents, characterisation, health claims. 
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INFORMATION AS PROVIDED IN THE CONSOLIDATED LIST 
The consolidated list of health claims pursuant to Article 13 of Regulation (EC) No 1924/2006
4
 
submitted by Member States contains main entry claims with corresponding conditions of use and 
literature for similar health claims. EFSA has screened all health claims contained in the original 
consolidated list of Article 13 health claims which was received by EFSA in 2008 using six criteria 
established by the NDA Panel to identify claims for which EFSA considered sufficient information 
had been provided for evaluation and those for which more information or clarification was needed 
before evaluation could be carried out
5
. The clarifications which were received by EFSA through the 
screening process have been included in the consolidated list. This additional information will serve 
as clarification to the originally provided information. The information provided in the consolidated 
list for the health claims which are the subject of this opinion is tabulated in Appendix C. 
ASSESSMENT 
The approach used in the evaluation of Article 13(1) health claims is explained in the general 
guidance for stakeholders on the evaluation of Article 13.1, 13.5 and 14 health claims
6
.  
In assessing each specific food/health relationship that forms the basis of a health claim the NDA 
Panel considers the extent to which:   
1. the food/constituent is defined and characterised;  
2. the claimed effect is defined and is a beneficial physiological effect (―beneficial to human health‖);   
3. a cause and effect relationship is established between the consumption of the food/constituent and 
the claimed effect (for the target group under the proposed conditions of use).  
Substantiation of the claim is dependent on a favourable outcome of the assessment of 1, 2 and 3 
above. Thus, a cause and effect relationship is considered not to be established if the outcome of any 
one of these assessments is unfavourable.  
For a claim, each relationship between a food/constituent and a claimed effect is assessed separately, 
and individual assessments are combined, as appropriate, to form coherent opinions. 
1. Characterisation of the food/constituent  
1.1. Combination of millet seed extract, L-cystine and pantothenic acid (ID 1514)  
The food that is the subject of the health claim is a combination of millet seed extract, L-cystine and 
pantothenic acid related to the following claimed effect: contribution to normal hair growth. 
The millets are a group of small-seeded species of cereal crops or grains, widely grown around the 
world for food and feed use. The millet species which is the source for the millet extract has not been 
specified in the information provided. Details on the extraction method and the composition of the 
whole-millet seed extract have been given with regard to several nutrients (fatty acids, protein/amino 
acids, minerals). However, from the references provided the Panel notes that the triterpenoid miliacin 
                                                     
4  Regulation (EC) No 1924/2006 of the European Parliament and of the Council of 20 December 2006 on nutrition and 
health claims made on foods. OJ L 404, 30.12.2006, p. 9–25.  
5  EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), 2011. General guidance for stakeholders on the 
evaluation of Article 13.1, 13.5 and 14 health claims. EFSA Journal, 9(4):2135, 24 pp. 
6 See footnote 5 
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contained in the millet seed extract was indicated as one of the active constituents of the combination 
in relation to the claimed effect. The amount of miliacin in the extracts was not specified. L-cystine 
and pantothenic acid are well recognised nutrients and are measurable in foods by established 
methods. 
The Panel considers that whereas L-cystine and pantothenic acid are sufficiently characterised, the 
millet extract, and hence the food, a combination of millet extract, L-cystine and pantothenic acid, 
which is the subject of the claim, is not sufficiently characterised in relation to the claimed effect 
considered in this section. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of a combination of millet seed extract, L-cystine and pantothenic acid and the claimed 
effect considered in this section. 
1.2. Amino acids (ID 1711) 
The food constituent that is the subject of the health claim is amino acids related to the following 
claimed effect: skeletal muscle tissue repair and recovery following strenuous exercise. 
Amino acids are the monomers from which proteins are built. Each amino acid has specific structural 
and chemical properties which affect the metabolic role of the free amino acid, and the behaviour of 
the amino acid residue within a protein. Different amino acids may have different effects on the 
stimulation of protein synthesis and breakdown. 
The Panel notes that the information in the consolidated list and the references provided did not allow 
characterisation of the specific amino acid or amino acid combination which is the subject of the 
health claim. 
The Panel considers that the food constituent, amino acids, which is the subject of the claim, is not 
sufficiently characterised. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of amino acids and the claimed effect considered in this section. 
1.3. Carbohydrate and protein combination (ID 461) 
The food that is the subject of the health claim is a combination of carbohydrates and protein related 
to the following claimed effect: faster skeletal muscle recovery after exercise. 
The Panel notes that the information provided in the consolidated list does not specify the nature and 
precise amounts of the carbohydrates or protein in the combination. 
In the references provided, various sources of carbohydrates and protein were used in different 
amounts and ratios. The Panel notes that from the references provided it is unclear to which type of 
carbohydrate and protein combination the claim refers. 
The Panel considers that the food, a combination of carbohydrates and protein, which is the subject of 
the claim, is not sufficiently characterised. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of a combination of carbohydrates and protein and the claimed effect considered in this 
section. 
Health claims related to not sufficiently characterised foods/food constituents  
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1.4. Ribes nigrum L. (ID 2191) 
The food that is subject of the health claim is Ribes nigrum L. related to the following claimed effect: 
maintenance of normal muscles and joints. 
Ribes nigrum L. (blackcurrant) is a perennial small shrub which is cultivated for food use mainly for 
its fruits. 
The proposed conditions of use for this claim refer to the leaves, which are to be used for the 
preparation of infusions. The references provided were related to proanthocyanidins and 
prodelphinidins isolated from blackcurrant leaves, and to anthocyanins from a commercially available 
blackcurrant juice. The leaves of Ribes nigrum L. contain flavonol gylcosides, proanthocyanidins of 
various degrees of polymerisation, dimeric prodelphinidins and a trimeric prodelphinidin (Blaschek et 
al., 2008). The Panel notes that from the information provided in the consolidated list and the 
references cited it is unclear to which specific preparation of Ribes nigrum L. the claim refers. 
The Panel considers that the food, Ribes nigrum L., which is the subject of the claim, is not 
sufficiently characterised. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of Ribes nigrum L. and the claimed effect considered in this section. 
1.5. Vitis vinifera L. (ID 2157) 
The food that is the subject of the health claim is Vitis vinifera L. related to the following claimed 
effect: maintenance of normal venous blood flow. 
Vitis vinifera L. is a liana which is cultivated for food use mainly for its fruits (i.e. grape). 
The leaves of Vitis vinifera L. contain flavonoids (flavonols and anthocyans), tannins (catechins, 
procyanidins, ellagitannins) as well as hydroxycinnamic acid derivatives and, depending on the 
variety, different amounts of cyanogenic glycosides. The fruits contain tartaric acid, malic acid, 
anthocyans and tannins, as well as essential oils containing linalool, geraniol, nerol, α-terpineol and 
phenylethanol. In the skin of the fruits, trans-resveratrol and pterostilben, as well as dimers and 
oligomers, are found. The seeds of Vitis vinifera L. contain 6-20 % fat, of which around 55 % is 
linoleic acid and 37 % oleic acid, and are rich in oligomeric procyanidins (Blaschek et al., 2008). 
The proposed conditions of use for this claim refer to the fruits, leaves and seeds, which are to be 
consumed in various forms and amounts, as well as to a specific leaf extract for which the flavonol 
content is given and the main flavonols were identified (i.e. quercetin-3-O-ß-D-glucuronide and 
quercetin-3-O-ß-glucoside). The references provided were related to extracts from red vine leaves, 
grape skin and grape seeds, respectively. In addition, monographs on Vitis vinifera L. and reviews on 
the effects of polyphenolic flavonoids were provided.  
The Panel notes that from the information in the consolidated list and the references provided it is 
unclear to which specific preparation of Vitis vinifera L. the claim refers. 
The Panel considers that the food, Vitis vinifera L., which is the subject of the claim, is not 
sufficiently characterised. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of Vitis vinifera L. and the claimed effect considered in this section. 
Health claims related to not sufficiently characterised foods/food constituents  
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1.6. Grifola frondosa (Maitake) (ID 2556) 
The food that is the subject of the health claim is Grifola frondosa (Maitake) related to the following 
claimed effect: blood glucose control. 
Grifola frondosa is a Basidiomycete fungus belonging to the family Polyporaceae, order 
Aphyllopherales (Lee et al., 2003). Its edible fruit bodies, known as Maitake in Japanese, consist of 
approximately 86 % moisture and 14 % dry matter, of which carbohydrates represent 59 %, protein 
21 %, fibre 10 %, fat 3 % and ash 7 % (Mau et al., 2001; Svagelij et al., 2008).  
The proposed conditions of use for this claim refer to the whole mushroom. However, the references 
provided were related to various preparations of Grifola frondosa, including powdered fruit bodies 
and a specific glycoprotein extract. 
The Panel notes that from the information in the consolidated list and the references provided it is 
unclear to which specific preparation of Grifola frondosa the claim refers. 
The Panel considers that the food, Grifola frondosa, which is the subject of the claim, is not 
sufficiently characterised. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of Grifola frondosa and the claimed effect considered in this section. 
1.7. Juice concentrate from berries of Vaccinium macrocarpon Aiton and Vaccinium 
vitis-idaea L. (ID 1125, 1288) 
The food that is the subject of the health claims is a mixture of juice from American cranberry 
(Vaccinium macrocarpon Aiton) and lingonberry (Vaccinium vitis-idaea L.) related to the following 
claimed effect: defence against bacterial pathogens in the lower urinary tract. 
According to the American Herbal Pharmacopeia and Therapeutic Compendium monograph (Upton, 
2002), ―cranberry fruit‖ consists of the fresh or dried whole, crushed or powdered mature fruits of 
Vaccinium macrocarpon Aiton (American cranberry, large cranberry, bearberry). Vaccinium 
macrocarpon Aiton belongs to the genus Vaccinum of the family Ericaceae. Cranberry (Vaccinium 
macrocarpon Aiton) fruits contain anthocyanins, tannins, catechins, flavonol glycosides, 
proanthocyanidins, organic acids such as quinic, malic and citric acids, and sugars such as glucose 
and fructose (Blumenthal, 2003). Vaccinium vitis-idaea L. (lingonberry), also called ―European 
cranberry‖ or mountain cranberry, is a species closely related to Vaccinium macrocarpon Aiton. 
From the information provided, the Panel notes that proanthocyanidins from cranberries and 
lingonberries have been indicated as being among the active constituents of the combination in 
relation to the claimed effect. 
Only one human intervention study conducted with a juice product derived from berries of Vaccinium 
macrocarpon Aiton and Vaccinium vitis-idaea L. was provided (Kontiokari et al., 2001). The product 
used in the study was a 9.2 g juice concentrate containing 7.5 g juice concentrate from berries of 
Vaccinium macrocarpon Aiton and 1.7 g juice concentrate from berries of Vaccinium vitis-idaea L. 
diluted in 50 mL of water. No information was provided on the grade of concentration, on the 
proanthocyanidin content, on the proanthocyanidin profile or on any of the other compounds in the 
juice which was used for the intervention. 
The Panel considers that the food, juice concentrate from berries of Vaccinium macrocarpon Aiton 
and Vaccinium vitis-idaea L., which is the subject of the claim, is not sufficiently characterised in 
relation to the claimed effect considered in this section.  
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10 EFSA Journal 2011;9(6):2244 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of a juice concentrate from berries of Vaccinium macrocarpon Aiton and Vaccinium 
vitis-idaea L. and the claimed effect considered in this section. 
1.8. Blueberry juice drink and blueberry extracts (ID 1370, 2638) 
The foods that are the subject of the claim are blueberry juice drink and blueberry extracts related to 
the following claimed effects: maintenance of normal vision and improvement of visual adaptation to 
the dark. 
The only reference provided was not related to the food which is the subject of the claim, but rather 
addressed the effect of billberry-extracted anthocyanosides on night vision.  
The Panel notes that the conditions of use and the reference provided do not allow the 
characterisation of the foods which are the subject of the claim.  
The Panel considers that the foods, blueberry juice drink and blueberry extracts, which are the subject 
of the claim, are not sufficiently characterised in relation to the claimed effects considered in this 
section.  
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of blueberry juice drink and blueberry extracts and the claimed effects considered in this 
section. 
1.9. Combination of anthocyanins from bilberry and blackcurrant (ID 2796) 
The food that is a subject of the claims is a combination of anthocyanins from bilberry and 
blackcurrant related to the following claimed effect: improvement of visual adaptation to the dark and 
reduction of ocular discomfort. 
Anthocyanins belong to the group of phenolic constituents known as flavonoids. They occur in foods 
as glycosylated anthocyanidins. The anthocyanin content in different types of berries, fruits and other 
plants is measurable by established methods. Typically the anthocyanin profile of berries consists of 
up to 16 different anthocyanins including different glycosides of cyanidin, delphinidin and other 
anthocyanidins. The anthocyanin profile in different types of berries varies depending on the type of 
berry, and may have an impact on the claimed effects.  
The references provided were either on bilberry or blackcurrant anthocyanins, but not on the 
combination of the two ingredients. The Panel considers that in the absence of evidence for the 
substantiation of the claim from studies on the combination for which the claim is made, studies on 
individual constituents cannot be used for substantiation. The Panel also notes that the conditions of 
use and the references provided do not allow the specification of the anthocyanin profile of the food 
which is the subject of the claims.  
The Panel considers that the food, a combination of anthocyanins from bilberry and blackcurrant, 
which is the subject of the claims, is not sufficiently characterised in relation to the claimed effects 
considered in this section. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of a combination of anthocyanins from bilberry and blackcurrant and the claimed effects 
considered in this section. 
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1.10. Inulin-type fructans (ID 766, 767, 768, 769, 770, 771, 772, 804, 848, 849, 2922, 3092)  
The food constituents that are the subject of the health claims are 
―inulin/oligofructose/oligofructose-enriched inulin (specific selection of short & long chains) from 
chicory‖, ―inulin/FOS (ß2→1 linked fructans)‖, ―inulin/oligofructose from chicory‖, 
―oligofructose-enriched inulin (specific selection of short & long chains) from chicory‖ and 
―inulin/oligofructose‖ and ―prebiotics‖ related to the following claimed effects: bowel function, 
defence against gastrointestinal pathogens, increase in calcium absorption and retention, increase in 
bone mineral density, maintenance of normal blood glucose concentrations, and satiety. 
From the conditions of use related to these claims and from the references provided, the Panel 
assumes that the food constituents, which are the subject of the claims, are mixtures of inulin and 
oligofructose from chicory, substances known as inulin-type fructans. 
Inulin-type fructans are linear polymers consisting of fructose molecules with mainly (or exclusively) 
β (2→1) linkages. They are extracted industrially from chicory. The term inulin-type fructans covers 
three types of chemical compounds: oligofructose (degree of polymerisation 2–8, average degree of 
polymerisation 4), native inulin (degree of polymerisation 2–60, average degree of 
polymerisation 12), and inulin HP (highly polymerised) (degree of polymerisation 10–60, average 
degree of polymerisation 25), or specific combinations of oligofructose and inulin. Native chicory 
inulin is a non-fractionated inulin extracted from fresh roots, which always contains glucose, fructose, 
sucrose and small oligosaccharides. About 10 % of the fructan chains in native chicory inulin have a 
degree of polymerisation ranging between 2 and 5. The partial enzymatic hydrolysis of inulin using an 
endo-inulinase produces oligofructose with degrees of polymerisation between 2 and 7. In 
oligofructose-enriched inulin, low and high molecular weight compounds are mixed. Long-chain 
inulin or inulin HP is produced by applying physical separation techniques to eliminate all oligomers 
with degrees of polymerisation <10. The term inulin is used to identify both native chicory inulin and 
any other derived industrial products except oligofructose (Roberfroid, 2005). 
The references provided for the scientific substantiation of the health claims related to gut microbiota 
and changes in bowel function used native inulin from chicory (e.g. Bouhnik et al., 2007; Causey et 
al., 2000; Den Hond et al., 2000; Gibson et al., 1995a; Kleessen et al., 1997a, 1997b), highly 
polymerised inulin (e.g. Tuohy et al., 2001), Jerusalem artichoke inulin (Kleessen et al., 2007), 
fructo-oligosaccharides (FOS) from chicory (Menne et al., 2000), FOS from sucrose (e.g. Bouhnik et 
al., 1999; Mitsuoka et al., 1987; Tokunaga et al., 1993), FOS from unknown origin (e.g. Buddington 
et al., 1996; Rao, 2001), or a mixture of FOS, glucose, fructose, and sucrose (e.g. Boutron-Ruault et 
al., 2005). The references provided for the scientific substantiation of the health claims related to 
calcium absorption and bone mineral density used 1:1 mixtures of oligofructose and long-chain inulin 
from chicory (e.g. Abrams et al., 2005), mixtures of 92 % inulin and 8 % short-chain oligofructose 
(e.g. Kruger et al., 2003), FOS from chicory (e.g. Kim et al., 2004; Lobo et al., 2006), native inulin 
from chicory (e.g. Roberfroid et al., 2002), or oligofructans with various degrees of polymerisation. 
The references provided for the scientific substantiation of the health claims related to satiety used 
native inulin from chicory or commercial inulin preparations not better described (e.g. Archer et al., 
2004), inulin HP (e.g. Cani et al., 2004), FOS from chicory (e.g. Cani et al., 2005; 2006), or FOS from 
unknown origin (e.g. Whelan et al., 2006). Similarly, the references provided for the scientific 
substantiation of the health claims related to blood cholesterol concentrations used mixtures of inulin 
and FOS from chicory (e.g. Brighenti et al., 1999), FOS from chicory (e.g. Alles et al., 1999), or 
native inulin from chicory (e.g. Causey et al., 2000; Davidson and Maki, 1999). 
The Panel notes that the food constituents described in relation to the health claims, and the food 
constituents used in the references provided for scientific substantiation, include a wide variety of 
inulin-type fructans with variable degrees of polymerisation, which could have an impact on the 
claimed effects. 
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The Panel considers that the food constituents, inulin-type fructans, which are the subject of the 
health claims, are not sufficiently characterised in relation to the claimed effects considered in this 
section. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of inulin-type fructans and the claimed effects considered in this section. 
1.11. Green clay (ID 347, 1952) 
The food constituent that is the subject of the claims is green clay related to the following claimed 
effect: reduction of gastro-intestinal discomfort. 
The term ―clay‖ is an ambiguous geological term and has multiple meanings: a group of fine grained 
minerals (clay minerals), a particle size (smaller than silt), or a type of rock (sedimentary deposits of 
fine-grained material usually composed largely of various clay minerals). In the latter definition, clay 
also includes fine-grained deposits of non-aluminosilicates (such as shale and non argillaceous soils) 
(WHO, 2005). In mineralogical definitions, clay minerals are composed of crystals less than 2 µm in 
diameter. 
Clays may be composed of different minerals, e.g. montmorillonite, beidellite, biotite, saponite, 
sauconite, kaolinite, bentonite, illite and sepiolite. The colour is not of great utility in defining clays: 
it mainly depends upon the content and form of the iron present. Green clays comprise minerals that 
differ by their composition, mineral structure, or geological occurrence (Velde, 2004).  
Several factors could determine the extent of clays’ adsorption properties, e.g. the chemistry of the 
clay minerals, exchangeable ions, the surface properties and the fine structure of clay particles 
(Williams et al., 2008). 
In relation to ID 347, the references provided were text books and general reviews not related to the 
food constituent which is the subject of the claim, but rather to magnesium or other micronutrients. 
No information was provided allowing the characterisation of green clay in relation to the claimed 
effect.  
In relation to ID 1952, the five references cited which addressed outcomes related to gastro-intestinal 
discomfort included the use of dioctahedral smectite (Chang et al., 2007; Guarino et al., 2001) or of 
beidellitic montmorillonite (Bedelix) (Bigard and Gilbert, 1990; Ducrotte et al., 2005; Meknini and 
Bernardes, 1994). The Panel notes that different types of green clays were used in the references 
provided, and that the conditions of use did not specify the green clay which is the subject of the 
health claim. The Panel notes that the conditions of use and the references provided do not allow the 
characterisation of the food constituent which is the subject of the claim.  
The Panel considers that the food constituent, green clay, which is the subject of the claim, is not 
sufficiently characterised in relation to the claimed effect considered in this section. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of green clay and the claimed effect considered in this section. 
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1.12. Foods and beverages “low in energy”, “energy-free” and “energy-reduced” (ID 1146, 
1147)  
The food that is the subject of the health claims is ―food reduced/low/free of energy‖ and ―beverages 
low/free of energy‖ related to the following claimed effects: body weight management. 
The conditions of use in relation to these claims refer to the provisions laid down in the Annex of 
Regulation (EC) No 1924/2006 on nutrition and health claims made on foods: 
- A claim that a food is low in energy may only be made where the product does not contain more 
than 40 kcal (170 kJ)/100 g for solids or more than 20 kcal (80 kJ)/100 mL for liquids.  
- A claim that a food is energy-free may only be made where the product does not contain more 
than 4 kcal (17 kJ)/100 mL.  
- A claim that a food is energy-reduced may only be made where the energy value is reduced by at 
least 30 %, with an indication of the characteristic(s) which make(s) the food reduced in its total 
energy value. 
The Panel notes that whereas the absolute energy content required in foods and beverages to qualify 
for a ―low in energy‖, and for an ―energy-free‖, claim is specified, it is not for ―energy-reduced‖ 
claims.  
The vast majority of the references provided for the scientific substantiation of these claims were 
observational (cross-sectional and prospective cohort) studies which assessed the effects of 
sugar-sweetened soft drink consumption on body weight, and on the effects of lifestyle (including 
television-watching, physical activity patterns, consumption of meals outside home, and consumption 
of certain types of meals, such as fast food menus and meat products) and level of education on body 
weight changes and obesity prevalence, mostly in children. Only a few human intervention studies, 
which assessed the effects of consuming sugar-sweetened beverages vs. sugar-free beverages 
containing intense sweeteners, have been provided, and no studies on the effects of consuming 
―low-energy‖ or ―energy-free‖ solid foods on body weight, either per se or in replacement of ―energy 
dense‖ or ―higher energy‖ foods, have been provided. 
Therefore, from the information provided, the Panel assumes that foods and beverages ―low in 
energy‖, ―energy-free‖ and ―energy-reduced‖ should replace ―energy dense‖ food or beverages in 
order to obtain the claimed effects. However, no information regarding the amount, frequency of 
consumption and/or the foods or beverages which should be replaced by foods and beverages ―low in 
energy‖, ―energy-free‖ or ―energy-reduced‖ in order to obtain the claimed effects has been provided; 
the only exception being foods and beverages containing intense sweeteners in replacement of 
sugar-sweetened foods and beverages. 
A claim on foods and beverages containing intense sweeteners in replacement of sugar and 
maintenance or achievement of a normal body weight has already been assessed with an unfavourable 
outcome (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 2011b).  
The Panel considers that foods and beverages ―low in energy‖, ―energy-free‖ or ―energy-reduced‖, 
and the ―energy dense‖ or ―higher energy‖ foods and beverages which they should replace, are not 
sufficiently characterised in relation to the claimed effects considered in this section. 
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of foods and beverages ―low in energy‖, ―energy-free‖ or ―energy-reduced‖ and the 
claimed effects considered in this section. 
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1.13. Carbohydrate foods and beverages (ID 458, 459, 470, 471, 654, 1277, 1278, 1279) 
The food constituent that is the subject of the health claims is carbohydrate foods and beverages 
related to the following claimed effects: physical capacity and performance in relation to short-term 
and endurance exercise (including endurance capacity and performance during the subsequent 
exercise bout after strenuous exercise) by contributing to the replenishment of muscle and liver 
glycogen stores, reduction in rated perceived exertion/effort during exercise, and recovery from 
muscle fatigue after exercise. The clarifications provided by Member States and the wordings and 
conditions of use proposed in relation to these claims, refer to ―foods for sports people under the 
Directive 89/398/EEC‖, to ―metabolisable carbohydrates‖, to ―low or high GI carbohydrates‖, to 
particular carbohydrates (e.g. glucose, glucose polymers and sucrose), and to ―carbohydrate rich 
diets‖.  
The Panel notes that ―foods for sports people under the Directive 89/398/EEC‖ are currently not 
regulated in the European Union, and that Council Directive 89/398/EEC
7
 does not provide any 
information that could be used for the characterisation of such foods, either in general or regarding 
their carbohydrate content. The Panel also notes that no information has been provided which could 
be used for the characterisation of ―carbohydrate-rich diets‖ in relation to the claimed effects.  
The claims considered in this section also refer to carbohydrate-containing foods and beverages with a 
high (vs. a low) glycaemic index (GI). Taking into account that the chemical nature of the 
carbohydrate-containing foods and beverages which are the subject of the health claims has not been 
defined, that the GI of different carbohydrate-containing foods or beverages depends on the chemical 
and physical properties of the particular foods or beverages under consideration, and that high 
(vs. low) GI carbohydrate-containing foods and beverages have not been defined in the information 
provided in relation to the standardisation of the testing method, the Panel considers that 
carbohydrate-containing foods and beverages with a high GI are not sufficiently characterised in 
relation to the claimed effects (EFSA Panel on Dietetic Products Nutrition and Allergies (NDA), 
2010b). 
The Panel assumes that ―metabolisable carbohydrates‖ refers to digestible, available or glycaemic 
carbohydrates which are digested and absorbed in the human small intestine providing carbohydrates 
to body cells. Main glycaemic carbohydrates in the diet are glucose and fructose (monosaccharides), 
sucrose and lactose (disaccharides), malto-oligosaccharides and starch (polysaccharides). The rate of 
digestion and absorption of available carbohydrates in foods and beverages is widely variable, and 
depends on the chemical structure, physical properties and macronutrient composition of the food or 
beverage in which carbohydrates are contained (EFSA Panel on Dietetic Products Nutrition and 
Allergies (NDA), 2010a).  
The vast majority of the references provided for the scientific substantiation of these claims addressed 
the effects of the amount, type and timing of administration of different carbohydrate-containing 
foods, beverages (usually as carbohydrate-containing electrolyte solutions), meals and diets on the 
claimed effects. Most of the human intervention studies provided compared the effects of various 
isoenergetic beverages containing different types of available carbohydrates (e.g. sucrose vs. 
maltodextrin vs. glucose vs. fructose vs. glucose polymers, or in different combinations) relative to 
other isoenergetic carbohydrate-containing beverages or to a hypoenergetic, carbohydrate-free 
placebo. The remaining studies compared the effects of low vs. high GI foods and meals, the effects 
of the timing of administration of carbohydrate-containing foods and beverages prior, during and after 
exercise, and the effects of different amounts and different timings of administration of carbohydrate-
containing foods and beverages on the replenishment of glycogen stores before and after exercise.  
                                                     
7  Council Directive 89/398/EEC of 3 May 1989 on the approximation of the laws of the Member States relating to 
foodstuffs intended for particular nutritional uses. OJ L 186, 30.6.1989, p. 27-32. 
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The evidence provided by consensus opinions/reports from authoritative bodies and reviews shows 
that macronutrient recommendations for athletes as % of total energy intake are not different from 
those for the general population (IoM, 2005), albeit higher amounts of carbohydrates may be required 
before, during and after exercise to maintain or improve exercise capacity and performance along with 
adequate hydration. An opinion on carbohydrate/electrolyte solutions and endurance performance has 
already been assessed with a favourable outcome (EFSA Panel on Dietetic Products Nutrition and 
Allergies (NDA), 2011a). However, whether and to what extent the consumption of available 
carbohydrate-containing foods and beverages influences exercise capacity/performance, perception of 
fatigue during exercise, and recovery from exercise may depend inter alia on the amount (absolute 
and relative to energy needs), form (solid vs. liquid) and type (e.g. rate of digestibility and 
availability) of the carbohydrates consumed, on other components of carbohydrate-containing foods 
and beverages (e.g. water, macro- and micronutrient composition and dietary fibre), on the intensity, 
duration and type of physical exercise performed, and on the time of administration (Burke and 
Hawley, 2006; Jeukendrup, 2004; Rodriguez et al., 2009; SCF, 2001). 
The Panel notes that carbohydrate foods and beverages have not been sufficiently characterised in the 
information provided with respect to the composition and conditions of use for the proposed claimed 
effects.  
The Panel concludes that a cause and effect relationship cannot be established between the 
consumption of carbohydrate foods and beverages and the claimed effects considered in this section. 
CONCLUSIONS  
On the basis of the data presented, the Panel concludes: 
 That the following foods/food constituents are not sufficiently characterised, or are not 
sufficiently characterised in relation to the proposed claimed effects: 
 Combination of millet seed extract, L-cystine and pantothenic acid related to: contribution to 
normal hair growth (ID 1514). 
 Amino acids related to: skeletal muscle tissue repair and recovery following strenuous 
exercise (ID 1711). 
 Carbohydrate and protein combination related to: faster skeletal muscle recovery after 
exercise (ID 461). 
 Ribes nigrum L. related to: maintenance of normal muscles and joints (ID 2191). 
 Vitis vinifera L. related to: maintenance of normal venous blood flow (ID 2157). 
 Grifola frondosa related to: blood glucose control (ID 2556). 
 Juice concentrate from berries of Vaccinium macrocarpon Aiton and Vaccinium vitis-idaea L. 
related to: defence against bacterial pathogens in the lower urinary tract (ID 1125, 1288). 
 Blueberry juice drink and blueberry extracts related to: maintenance of normal vision and 
improvement of visual adaptation to the dark (ID 1370, 2638). 
 Combination of anthocyanins from bilberry and blackcurrant related to: improvement of 
visual adaptation to the dark and reduction of ocular discomfort (ID 2796). 
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 Inulin-type fructans related to: bowel function, defence against gastrointestinal pathogens, 
increase in calcium absorption and retention, increase in bone mineral density, maintenance 
of normal blood glucose concentrations, and satiety (ID 766, 767, 768, 769, 770, 771, 772, 
804, 848, 849, 2922, 3092). 
 Green clay related to: reduction of gastro-intestinal discomfort (ID 347, 1952). 
 Foods and beverages ―low in energy‖, ―energy-free‖ and ―energy-reduced‖ related to: body 
weight management (ID 1146, 1147). 
 Carbohydrate foods and beverages related to: physical capacity and performance in relation to 
short-term and endurance exercise (including endurance capacity and performance during the 
subsequent exercise bout after strenuous exercise) by contributing to the replenishment of 
muscle and liver glycogen stores, reduction in rated perceived exertion/effort during exercise, 
and recovery from muscle fatigue after exercise (ID 458, 459, 470, 471, 654, 1277, 1278, 
1279). 
 A cause and effect relationship cannot be established between the foods/food constituents which 
are the subject of this opinion and the claimed effects. 
DOCUMENTATION PROVIDED TO EFSA 
Health claims pursuant to Article 13 of Regulation (EC) No 1924/2006 (No: EFSA-Q-2008-1134, 
EFSA-Q-2008-1245, EFSA-Q-2008-1246, EFSA-Q-2008-1248, EFSA-Q-2008-1257, EFSA-Q-2008-
1258, EFSA-Q-2008-1441, EFSA-Q-2008-1553, EFSA-Q-2008-1554, EFSA-Q-2008-1555, EFSA-Q-
2008-1556, EFSA-Q-2008-1557, EFSA-Q-2008-1558, EFSA-Q-2008-1559, EFSA-Q-2008-1591, 
EFSA-Q-2008-1635, EFSA-Q-2008-1636, EFSA-Q-2008-1864, EFSA-Q-2008-1885, EFSA-Q-2008-
1886, EFSA-Q-2008-2015, EFSA-Q-2008-2016, EFSA-Q-2008-2017, EFSA-Q-2008-2026, EFSA-Q-
2008-2107, EFSA-Q-2008-2251, EFSA-Q-2008-2447, EFSA-Q-2008-2685, EFSA-Q-2008-2890, 
EFSA-Q-2008-2924, EFSA-Q-2008-3289, EFSA-Q-2008-3371, EFSA-Q-2008-3529, EFSA-Q-2008-
3655, EFSA-Q-2008-3824). The scientific substantiation is based on the information provided by the 
Member States in the consolidated list of Article 13 health claims and references that EFSA has 
received from Member States or directly from stakeholders. 
The full list of supporting references as provided to EFSA is available on: 
http://www.efsa.europa.eu/panels/nda/claims/article13.htm. 
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APPENDICES 
APPENDIX A 
BACKGROUND AND TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The Regulation 1924/2006 on nutrition and health claims made on foods
8
 (hereinafter "the 
Regulation") entered into force on 19
th
 January 2007. 
Article 13 of the Regulation foresees that the Commission shall adopt a Community list of permitted 
health claims other than those referring to the reduction of disease risk and to children's development 
and health. This Community list shall be adopted through the Regulatory Committee procedure and 
following consultation of the European Food Safety Authority (EFSA). 
Health claims are defined as "any claim that states, suggests or implies that a relationship exists 
between a food category, a food or one of its constituents and health".  
In accordance with Article 13 (1) health claims other than those referring to the reduction of disease 
risk and to children's development and health are health claims describing or referring to:  
a) the role of a nutrient or other substance in growth, development and the functions of the 
body; or 
b) psychological and behavioural functions; or 
c) without prejudice to Directive 96/8/EC, slimming or weight-control or a reduction in the 
sense of hunger or an increase in the sense of satiety or to the reduction of the available 
energy from the diet. 
To be included in the Community list of permitted health claims, the claims shall be:  
(i) based on generally accepted scientific evidence; and 
(ii) well understood by the average consumer. 
Member States provided the Commission with lists of claims as referred to in Article 13 (1) by 31 
January 2008 accompanied by the conditions applying to them and by references to the relevant 
scientific justification. These lists have been consolidated into the list which forms the basis for the 
EFSA consultation in accordance with Article 13 (3).  
ISSUES THAT NEED TO BE CONSIDERED 
IMPORTANCE AND PERTINENCE OF THE FOOD
9
  
Foods are commonly involved in many different functions
10
 of the body, and for one single food many 
health claims may therefore be scientifically true. Therefore, the relative importance of food e.g. 
nutrients in relation to other nutrients for the expressed beneficial effect should be considered: for 
functions affected by a large number of dietary factors it should be considered whether a reference to 
a single food is scientifically pertinent.  
                                                     
8 OJ L12, 18/01/2007 
9 The term 'food' when used in this Terms of Reference refers to a food constituent, the food or the food category.  
10 The term 'function' when used in this Terms of Reference refers to health claims in Article 13(1)(a), (b) and (c).  
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It should also be considered if the information on the characteristics of the food contains aspects 
pertinent to the beneficial effect.  
SUBSTANTIATION OF CLAIMS BY GENERALLY ACCEPTABLE SCIENTIFIC EVIDENCE 
Scientific substantiation is the main aspect to be taken into account to authorise health claims. Claims 
should be scientifically substantiated by taking into account the totality of the available scientific 
data, and by weighing the evidence, and shall demonstrate the extent to which: 
(a) the claimed effect of the food is beneficial for human health, 
(b) a cause and effect relationship is established between consumption of the food and the 
claimed effect in humans (such as: the strength, consistency, specificity, dose-
response, and biological plausibility of the relationship), 
(c) the quantity of the food and pattern of consumption required to obtain the claimed 
effect could reasonably be achieved as part of a balanced diet, 
(d) the specific study group(s) in which the evidence was obtained is representative of the 
target population for which the claim is intended. 
EFSA has mentioned in its scientific and technical guidance for the preparation and presentation of 
the application for authorisation of health claims consistent criteria for the potential sources of 
scientific data. Such sources may not be available for all health claims. Nevertheless it will be 
relevant and important that EFSA comments on the availability and quality of such data in order to 
allow the regulator to judge and make a risk management decision about the acceptability of health 
claims included in the submitted list. 
The scientific evidence about the role of a food on a nutritional or physiological function is not 
enough to justify the claim. The beneficial effect of the dietary intake has also to be demonstrated. 
Moreover, the beneficial effect should be significant i.e. satisfactorily demonstrate to beneficially 
affect identified functions in the body in a way which is relevant to health. Although an appreciation 
of the beneficial effect in relation to the nutritional status of the European population may be of 
interest, the presence or absence of the actual need for a nutrient or other substance with nutritional or 
physiological effect for that population should not, however, condition such considerations. 
Different types of effects can be claimed. Claims referring to the maintenance of a function may be 
distinct from claims referring to the improvement of a function. EFSA may wish to comment whether 
such different claims comply with the criteria laid down in the Regulation. 
WORDING OF HEALTH CLAIMS 
Scientific substantiation of health claims is the main aspect on which EFSA's opinion is requested. 
However, the wording of health claims should also be commented by EFSA in its opinion. 
There is potentially a plethora of expressions that may be used to convey the relationship between the 
food and the function. This may be due to commercial practices, consumer perception and linguistic 
or cultural differences across the EU. Nevertheless, the wording used to make health claims should be 
truthful, clear, reliable and useful to the consumer in choosing a healthy diet. 
In addition to fulfilling the general principles and conditions of the Regulation laid down in Article 3 
and 5, Article 13(1)(a) stipulates that health claims shall describe or refer to "the role of a nutrient or 
other substance in growth, development and the functions of the body". Therefore, the requirement to 
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describe or refer to the 'role' of a nutrient or substance in growth, development and the functions of 
the body should be carefully considered. 
The specificity of the wording is very important. Health claims such as "Substance X supports the 
function of the joints" may not sufficiently do so, whereas a claim such as "Substance X helps 
maintain the flexibility of the joints" would. In the first example of a claim it is unclear which of the 
various functions of the joints is described or referred to contrary to the latter example which 
specifies this by using the word "flexibility". 
The clarity of the wording is very important. The guiding principle should be that the description or 
reference to the role of the nutrient or other substance shall be clear and unambiguous and therefore 
be specified to the extent possible i.e. descriptive words/ terms which can have multiple meanings 
should be avoided. To this end, wordings like "strengthens your natural defences" or "contain 
antioxidants" should be considered as well as "may" or "might" as opposed to words like 
"contributes", "aids" or "helps".  
In addition, for functions affected by a large number of dietary factors it should be considered 
whether wordings such as "indispensable", "necessary", "essential" and "important" reflects the 
strength of the scientific evidence. 
Similar alternative wordings as mentioned above are used for claims relating to different relationships 
between the various foods and health. It is not the intention of the regulator to adopt a detailed and 
rigid list of claims where all possible wordings for the different claims are approved. Therefore, it is 
not required that EFSA comments on each individual wording for each claim unless the wording is 
strictly pertinent to a specific claim. It would be appreciated though that EFSA may consider and 
comment generally on such elements relating to wording to ensure the compliance with the criteria 
laid down in the Regulation. 
In doing so the explanation provided for in recital 16 of the Regulation on the notion of the average 
consumer should be recalled. In addition, such assessment should take into account the particular 
perspective and/or knowledge in the target group of the claim, if such is indicated or implied. 
TERMS OF REFERENCE 
HEALTH CLAIMS OTHER THAN THOSE REFERRING TO THE REDUCTION OF DISEASE RISK AND TO 
CHILDREN'S DEVELOPMENT AND HEALTH 
EFSA should in particular consider, and provide advice on the following aspects:  
 Whether adequate information is provided on the characteristics of the food pertinent to the 
beneficial effect. 
 Whether the beneficial effect of the food on the function is substantiated by generally 
accepted scientific evidence by taking into account the totality of the available scientific data, 
and by weighing the evidence. In this context EFSA is invited to comment on the nature and 
quality of the totality of the evidence provided according to consistent criteria. 
 The specific importance of the food for the claimed effect. For functions affected by a large 
number of dietary factors whether a reference to a single food is scientifically pertinent.  
In addition, EFSA should consider the claimed effect on the function, and provide advice on the 
extent to which: 
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 the claimed effect of the food in the identified function is beneficial. 
 a cause and effect relationship has been established between consumption of the food and the 
claimed effect in humans and whether the magnitude of the effect is related to the quantity 
consumed. 
 where appropriate, the effect on the function is significant in relation to the quantity of the 
food proposed to be consumed and if this quantity could reasonably be consumed as part of a 
balanced diet.  
 the specific study group(s) in which the evidence was obtained is representative of the target 
population for which the claim is intended. 
 the wordings used to express the claimed effect reflect the scientific evidence and complies 
with the criteria laid down in the Regulation.  
When considering these elements EFSA should also provide advice, when appropriate: 
 on the appropriate application of Article 10 (2) (c) and (d) in the Regulation, which provides 
for additional labelling requirements addressed to persons who should avoid using the food; 
and/or warnings for products that are likely to present a health risk if consumed to excess. 
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APPENDIX B 
EFSA DISCLAIMER 
The present opinion does not constitute, and cannot be construed as, an authorisation to the marketing 
of the food/food constituent, a positive assessment of its safety, nor a decision on whether the 
food/food constituent is, or is not, classified as foodstuffs. It should be noted that such an assessment 
is not foreseen in the framework of Regulation (EC) No 1924/2006. 
It should also be highlighted that the scope, the proposed wordings of the claims and the conditions of 
use as proposed in the Consolidated List may be subject to changes, pending the outcome of the 
authorisation procedure foreseen in Article 13(3) of Regulation (EC) No 1924/2006. 
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APPENDIX C 
Table 1. Main entry health claims related to not sufficiently characterised foods/food constituents, 
including conditions of use from similar claims, as proposed in the Consolidated List. 
ID Food or Food constituent Health Relationship Proposed wording 
347 Argile verte Système digestif 
Antidiarrhéique. 
Améliore le confort digestif. 
Participe à l'absorption des toxines et 
des gaz se formant. 
au cours du processus de digestion 
Contribue au confort digestif. 
Conditions of use 
- 9g/jour. 
No clarification provided by Member States 
ID Food or Food constituent Health Relationship Proposed wording 
458 Carbohydrate. Energise. 
Re-energise post 
exercise. 
Clarification provided 
Available carbohydrates 
and optimal 
replenishment of 
glycogen stores in the 
body after exercise. 
Available carbohydrates 
must deliver at least 
51% of energy. 
Provides energy. 
Re-energises during and post 
exercise bouts. 
Conditions of use 
- none provided 
Comments from Member States 
Proposed amendments to Conditions of use: Available carbohydrates must deliver at least 51% 
of energy. 
ID Food or Food constituent Health Relationship Proposed wording 
459 Carbohydrates. Physical endurance. Carbohydrate-containing foods have 
a beneficial impact on exercise 
performance. 
Carbohydrate is a key energy source 
prior to exercise. 
Conditions of use 
- Metabolisable carbohydrates: = 65% of total energy (for foods). Metabolisable 
carbohydrates: = 75% of total energy (for beverages). 
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ID Food or Food constituent Health Relationship Proposed wording 
461 Carbohydrate and protein 
combination 
Clarification provided 
Carbohydrate and protein in 
sports nutrition products 
At least 20 g metabolisable 
carbohydrates (examples 
include glucose, glucose 
polymers, sucrose, fructose) 
per single serving and at least 
10g high biological value 
protein per single serving. 
Recovery Combination 
optimizes muscle 
glycogen and protein 
synthesis. 
Optimizes muscle glycogen and 
protein synthesis and muscle 
recovery. 
Helps to rebuild muscles after 
exercise (scientifically proven). 
Prepares for the next workout faster 
Jumpstart muscle recover. 
Helps muscles recover their energy - 
rebuild muscle glycogen, repair 
muscle protein 
Conditions of use 
- Claim to be only used for Foods for sportspeople under the Dir. 89/398/EEC. Contains 
metabolisable carbohydrates. Contains = 15g high quality protein per serve. 
ID Food or Food constituent Health Relationship Proposed wording 
470 Carbohydrate foods and 
beverages. 
Clarification provided 
Carbohydrate electrolyte food 
and drinks as defined in 
SCF/CS/NUT/SPORT/5 
Final. 
Claim to be only used for 
Foods for sports people under 
the Dir. 89/398/EEC. 
Composition & specification 
of carbohydrate electrolyte 
solutions must meet guidance 
as outlined in Scientific 
Committee for Food report 
on food intended to meet 
expenditure of intense 
muscular effort: 
For foods: 
Metabolisable carbohydrates: 
= 65% of total energy (for 
foods). 
For drinks: 
Energy levels ranging 
between 340-1488kJ/L (80-
350kcal/L). 
At least 75% of total energy 
should be derived from 
metabolisable carbohydrate 
Endurance: 
Increased endurance 
capacity;  
Increased endurance 
performance; 
Delayed Fatigue. 
Enhances / maximises glycogen 
stores. 
Carbohydrate before, during 
exercise improves endurance 
performance / perform for longer. 
Carbohydrate rich diets before 
exercise help elevate pre-exercise 
glycogen stores. 
Ingestion during exercise maintains 
blood glucose. 
Glucose is the body’s naturally 
preferred source of energy during 
intense exercise 
Consumption in events as short as 1 
hr improves exercise performance. 
Endurance capacity / time to 
exhaustion / delays fatigue. 
Carbohydrate loading can delay 
fatigue and benefits endurance and 
multiple sprint sports. 
Energy for endurance / fuel for your 
muscles. 
Carbohydrate before and after 
exercise extends endurance time and 
work output more than either alone. 
Glycogen Sparing. 
Clarification provided 
Enhances / maximises glycogen 
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characterized by a high 
glycaemic index (examples 
include glucose, glucose 
polymers, sucrose). 
Must also contain 20-50 
mmol/l (460-1150 mg/l) 
Sodium (as Na+). 
stores. Carbohydrate before, during 
exercise improves endurance 
performance / perform for longer. 
Carbohydrate rich diets before 
exercise help elevate pre-exercise 
glycogen stores. Ingestion during 
exercise maintains blood glucose. 
Glucose is the body’s naturally 
preferred source of energy during 
intense exercise Consumption in 
events as short as 1 hr improves 
exercise performance. Endurance 
capacity / time to exhaustion / delays 
fatigue Carbohydrate loading can 
delay fatigue and benefits endurance 
and multiple sprint sports. Energy 
for endurance / fuel for your 
muscles. Carbohydrate before and 
after exercise extends endurance 
time and work output more than 
either alone Glycogen Sparing. 
 Conditions of use 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Metabolisable 
carbohydrates: = 65% of total energy (for foods). Metabolisable carbohydrates: = 75% of 
total energy (for beverages). 
ID Food or Food constituent Health Relationship Proposed wording 
471 Carbohydrate foods and 
beverages. 
Clarification provided 
Carbohydrate foods and 
beverages. 
Carbohydrate (including 
glucose, glucose polymers, 
sucrose, fructose) in sports 
nutrition products. 
Recovery Enhanced 
muscle glycogen 
synthesis 
Enhanced recovery. 
Carbohydrate after exercise 
maximises muscle glycogen 
replacement. 
High GI carbohydrate post exercise 
results in higher muscle glycogen 
levels after 24 hours than low GI. 
Liquid carbohydrate is as effective 
as a solid form for glycogen 
resynthesis. 
Replaces glycogen stores used 
during exercise. 
Consumption at frequent intervals 
maintains enhanced muscle 
glycogen synthesis. 
Helps recovery and enhances 
subsequent performance / endurance 
capacity / delayed onset of fatigue. 
Carbohydrate during first hour after 
exercise assures maximal muscle 
glycogen resynthesis rate and speed 
of recovery 
Clarification provided 
Carbohydrate after exercise 
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maximises muscle glycogen 
replacement. High GI carbohydrate 
post exercise results in higher 
muscle glycogen levels after 24 
hours than low GI. Liquid 
carbohydrate is as effective as a 
solid form for glycogen resynthesis. 
Replaces glycogen stores used 
during exercise. Consumption at 
frequent intervals maintains 
enhanced muscle glycogen 
synthesis. Helps recovery and 
enhances subsequent performance / 
endurance capacity / delayed onset 
of fatigue. Carbohydrate during first 
hour after exercise assures maximal 
muscle glycogen resynthesis rate and 
speed of recovery. 
 Conditions of use 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Metabolisable 
carbohydrates: = 65% of total energy (for foods). Metabolisable carbohydrates: = 75% of 
total energy (for beverages). 
Comments from Member States 
UK Comment: At least 30 g metabolisable carbohydrates per single bolus serving. 
ID Food or Food constituent Health Relationship Proposed wording 
654 Carbohydrates. Reconstitution of liver 
and muscle glycogen 
stores. 
Carbohydrate-containing foods help 
to rebuild liver and muscle glycogen 
stores after exercise. 
Conditions of use 
- The carbohydrate concentration of carbohydrate-rich energy food products for athletes 
should exceed 10% of weight by volume (these are about 40 kcal/100 ml) and at least 75% 
of energy should be derived from metabolisable carbohydrates. 
ID Food or Food constituent Health Relationship Proposed wording 
766 Inulin / oligofructose / 
Oligofructose-enriched inulin 
(specific selection of short & 
long chains) from chicory 
Prebiotic / Bifidogenic -inulin/oligofructose/ oligofructose 
enriched inulin from chicory 
stimulates the growth of 
Bifidobacteria in the colon; 
-inulin/oligofructose/ oligofructose 
enriched inulin from chicory 
beneficially affects the intestinal 
flora; 
-inulin/oligofructose/ oligofructose 
enriched inulin from chicory 
promote healthy/balanced/good gut 
bacteria. 
Conditions of use 
- Amount of consumption: 5 Gramm (g) g/Tag Other condition: beginnt bei 5g/Tag. 
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- Erwachsene Amount of consumption: 40 Milliliter (ml) Period of consumption: 4 bis 6 
Wochen 
- Jugendliche, Erwachsene Amount of consumption: 200 Milliliter (ml) Period of 
consumption: 4 bis 6 Wochen 
- Amount of consumption: 2 Gramm (g) 3 mal am Tag Period of consumption: mindestens 7 
Tage Einnahme 
- Amount of consumption: 2 Gramm (g) 3 mal am Tag plus je 3 mal am Tag 1,6 g indische 
Flohsamenschale 
- Amount of consumption: 2 Gramm (g) 3 mal am Tag plus je 3 mal am Tag 1,6 g indische 
Flohsamenschale Period of consumption: Einnahmedauer ≥ 7 Tage Amount of 
consumption: 5 Gramm (g) g/Tag 
- 5g/ day 
- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated 5g/ day 
- Fruit drink with 1g/100g of inulin, 2.5g/serving, 5g/daily serving 
- Food supplement with 2g of inulin in the daily dose 
- Cereal products (mueslis and muesli snacks), with 4g/100g of inulin, 2g/serving and 
3g/100g of polydextrose, 1.5g/serving 
- Fruit and berry juices with 3g/100g of soluble and insoluble fibre, 6g/serving, 24g/daily 
serving Fibre comes from plant products, e.g. inulin or oligosaccharides. Certain types of 
fibre may be hydrolysed during processing and shelf life of the product in certain 
conditions. 
ID Food or Food constituent Health Relationship Proposed wording 
767 Inulin / FOS (ß2→1 linked 
fructans) 
Prebiotic/ Bifidogenic; 
Digestive Health 
-Inulin (or FOS) promotes healthy 
gut bacteria or microflora; 
-Inulin (or FOS) is a prebiotic; 
-Inulin (or FOS) is bifidogenic; 
-Inulin (or FOS) promotes good 
digestive health; 
-Inulin (or FOS) promotes 
gastrointestinal /bowel/gut/colonic 
health; 
- Prebiotics 
Conditions of use 
- Amount of consumption : 6 mal am Tag plus 6 mal 0,25 g Butyrat. Other condition: in einer 
Galenik (MMX), die die Inhaltsstoffe nur im Dickdarm, über dessen gesamten Verlauf 
freisetzt 
- Amount of consumption: 2 Gramm (g) 3 mal am Tag plus je 3 mal am Tag 1,6 g indische 
Flohsamenschale. Period of consumption: Einnahmedauer ≥ 7 Tage 
- Erwachsene, signifikante Menge im lebensmittel (mind. 3g / 100 g oder 100 kcal) 
- 5 Gramm (g) g/Tag 
- 8 Gramm (g) g/Tag 
- 5g/ day 
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- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated. 5g/ day 
- Tagesdosis Inulin: 810 mg–Erwachsene 
- Sonden- und Trinknahrungen 
- 4% im verzehrsfertigen Lebensmittel––Aufnahme 5g pro Tag 
ID Food or Food constituent Health Relationship Proposed wording 
768 Inulin/oligofructose from 
chicory  
Improved intestinal 
conditions (pH, SCFA 
production) and 
intestinal functions 
Clarification provided 
Improved intestinal 
conditions (pH, SCFA 
production) and 
intestinal functions. 
Chicory 
Inulin/oligofructose 
stimulates the growth of 
Bifidobacteria in the 
colon; Chicory 
inulin/oligofructose 
beneficially affects the 
intestinal flora; 
Prebiotics promote 
healthy gut bacteria; 
Chicory 
inulin/oligofructose 
promotes better 
intestinal flora.  
-inulin/oligofructose from chicory 
improves intestinal conditions; 
-inulin/oligofructose fron chicory 
promotes intestinal health. 
Conditions of use 
- 5 Gramm (g) g/Tag 
- 5 bis 10 Gramm (g) 
- 2 Gramm (g). 3 mal am Tag plus je 3 mal am Tag 1,6 g indische Flohsamenschale 
- Es werden nur die Nährstoffe beworben, die lt. Nährwertkennzeichnungs-verordnung 
(Anlage 1) mindestens 15 Prozent der empfohlenen Tagesdosis in 100 g oder 100 ml 
enthalten. 
- 5g/day 
- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated. 5g/day 
Comments from Member States 
UK Comment: Please see claim 804: same food, but given a code 4. Unlcear as to what must be 
clarified. 
ID Food or Food constituent Health Relationship Proposed wording 
769 Inulin / oligofructose / 
oligofructose-enriched inulin 
Improves digestive/ 
bowel function 
-promotes/ supports digestive health; 
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(specific selection of short & 
long chains) from chicory 
-improves bowel regularity; 
-improves digestive/ bowel function. 
Conditions of use 
- Amount of consumption: 8Gramm (g) g/Tag. Other condition: beginnt bei 8g/Tag 
- Amount of consumption: 8Gramm (g) g/Tag 
- Amount of consumption: 6 mal am Tag plus 6 mal 0,25 g Butyrat. Other condition: in einer 
Galenik (MMX), die die Inhaltsstoffe nur im Dickdarm, über dessen gesamten Verlauf 
freisetzt 
- Erwachsene. Amount of consumption: 40 Milliliter (ml). Period of consumption: 4 bis 6 
Wochen  
- Amount of consumption: 2 Gramm (g) 3 mal am Tag plus je 3 mal am Tag 1,6 g indische 
Flohsamenschale. Other condition: additiver Effekt beider Substanzen 
- Jugendliche, Erwachsene. Amount of consumption: 200Milliliter (ml). Period of 
consumption: 4 bis 6 Wochen 
- alle Personen. Amount of consumption: 5 Gramm (g) 1,5 pro Portion Period of 
consumption: täglich, mindestens 7 Tage Other condition: siehe 
http://www.gdch.de/strukturen/fg/lm/ag/ernaehrung/stellungnahmen/inulin.htm  
- 8 g/day 
- 8 g/Tag. beginnt bei 8g/Tag 
- Minimum 2 g in the daily portion of the product 
- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated 8g/day 
- Juices with 3g/100g of oligofructose, 6g/serving 
- beginnt bei 8g pro Tag  
ID Food or Food constituent Health Relationship Proposed wording 
770 Inulin/oligofructose from 
chicory 
Improved Calcium 
absorption 
inulin/ oligofructose enhances 
calcium absorption 
Conditions of use 
- Jugendliche, Erwachsene. Amount of consumption: 200 Milliliter (ml). Period of 
consumption: 4 bis 6 Wochen 
- 8 g/day 
- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated. 8g/day 
- beginnt bei 8g pro Tag  
ID Food or Food constituent Health Relationship Proposed wording 
771 Oligofructose-enriched inulin 
(specific selection of short & 
long chains) from chicory 
Increased calcium 
absorption 
increases/ promotes/ enhances 
Calcium absorption. 
Conditions of use 
- 8 Gramm (g) g/Tag 
- 5 bis 10 Gramm (g) 
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- 8 Gramm (g) g/Tag. Other condition: beginnt bei 8g/Tag 
- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated 8g/day 
ID Food or Food constituent Health Relationship Proposed wording 
772 Oligofructose-enriched inulin 
(specific selection of short & 
long chains) from chicory 
Increased bone mineral 
density 
-increased bone mineral density; 
-increased bone strength. 
Conditions of use 
- 8 Gramm (g) g/Tag 
- 8 Gramm (g) g/Tag. Other condition: beginnt bei 8g/Tag 
- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated 8g/day 
- 8 g/day 
- beginnt bei 8g pro Tag 
ID Food or Food constituent Health Relationship Proposed wording 
804 Inulin/ oligofructose from 
chicory  
Clarification provided 
Inulin/oligofructose from 
chicory  
At least 9 g/day 
(recommended amount per 
serving : 25%) 
Cholesterol maintenance inulin/ oligofructose from chicory : 
- helps to regulate cholesterol level; 
- contributes to healthy blood 
cholesterol level; 
- helps to manage cholesterol level; 
- helps to maintain healthy blood 
cholesterol level. 
Conditions of use 
- 9g/ day 
- 9 g/day (or minimum 25% of the daily dose per serving) 
- Where a daily value is indicated the amount per serving is typicaly 25% unless otherwise 
stated. 9g/day 
ID Food or Food constituent Health Relationship Proposed wording 
848 Inulin/oligofructose Improved intestinal 
conditions (pH, SCFA 
production) and 
intestinal functions 
1) Inulin/oligofructose stimulates the 
growth of Bifidobacteria in the 
colon; 2) Beneficially affects the 
intestinal flora; (3) Prebiotics 
promote healthy gut bacteria; (4) 
promotes a healthy bowel function; 
(5) Promotes better intestinal flora. 
A better intestinal flora supports 
your body’s defence system; (6) 
Prebiotic fibres support your natural 
defence 
Conditions of use 
- 5 g/day 
- 5 g/day, 5 g/ημέρα 
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- 4g/ day 
ID Food or Food constituent Health Relationship Proposed wording 
849 Inulin/oligofructose Improved Calcium/Ca 
absorption/uptake 
Inulin/oligofructose enhances 
calcium absorption 
Conditions of use 
- 8 g/Tag 
- 8g/ day 
ID Food or Food constituent Health Relationship Proposed wording 
1125 Cranberry (Lingonberry) 
juice, (Vaccinium vitis-idaea, 
Vaccinium macrocarpon). 
Urinary tract. 
Clarification provided 
Cranberry juice and its 
extracts help 
maintaining normal 
urination, and support 
healthy, pathogenic 
bacteria free urinary 
tract: 
Improves urinary tract 
health by reducing 
adherence of 
unfavourable bacteria 
(for example E. coli 
bacteria). 
Cranberry juice helps to keep the 
urinary system in a healthy 
condition; 
Lingonberry juice has a positive 
effect on the urinary tract; 
Cranberry juice has a beneficial 
effect on the urinary system. 
Conditions of use 
- 30ml /day 100% american cranberry juice or any extract equivalent with this 
(around;1200mg/day). 
- 50-90 ml of cranberry juice diluted into 300-500 of drinkable juice and 50 ml of 
lingonberry-cranberry concentrates prepared by diluting 7.5 g of cranberry juice concentrate 
and 1,7 g of lingonberry juice concentrate with water. 
- Verzehrfertiges Produkt (verdünnter Saft, Nektar oder Sirup) enthält 9,2 g Saftkonzentrat; 
täglich verzehrt über 12 Monate. 
- Tagesdosis Granulat: 1-2 Sachets (entsprechend: 225 mg Proanthocyanidine/Sachets)––
Tagesdosis Filmtabletten: 2 Filmtabletten (bis zu 12 Filmtabletten täglich) entsprechend 
32,4 mg Proanthocyanidine/Filmtablette. 
ID Food or Food constituent Health Relationship Proposed wording 
1146 Food reduced/ low/ free of 
energy. 
Clarification provided 
Food and beverage free of 
energy. According to the 
conditions of the Nutrition 
and Health Claims 
regulation Annex: foods 
which do not contain more 
than 4 kcal (17 kJ)/100ml. 
Body weight 
management. 
[x] helps maintain your body weight 
(as part of a calorie controlled diet). 
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Food and beverage low in 
energy. According to the 
conditions of the Nutrition 
and Health Claims 
regulation Annex: foods 
which do not contain more 
than 40 kcal (170 kJ)/100 g 
for solids or more than 20 
kcal (80 kJ)/100 ml for 
liquids. 
Conditions of use 
- Muss den relevanten Bestimmungen der ClaimsVO entsprechen. 
- Weniger Kalorien, mehr Ballaststoffe, weniger Zucker (Energie). 
- Gem Anforderung der Health Claim Regulation 1924/2006/EC. 
- Meet the relevant annex requirements in HC Regulation. 
Comments from Member States 
Note to Cion from submitter: please split this claim into two. 
ID Food or Food constituent Health Relationship Proposed wording 
1147 Beverages low / free of 
energy. 
Clarification provided 
Food and beverage free of 
energy. According to the 
conditions of the Nutrition 
and Health Claims 
regulation Annex: foods 
which do not contain more 
than 4 kcal (17 kJ)/100ml. 
Food and beverage low in 
energy. According to the 
conditions of the Nutrition 
and Health Claims 
regulation Annex: foods 
which do not contain more 
than 40 kcal (170 kJ)/100 g 
for solids or more than 20 
kcal (80 kJ)/100 ml for 
liquids. 
Body shape 
management. 
-Product x is energy free / low in 
energy…….. to help take care of your 
body shape/take care of your 
silhouette. 
-Product X, an ally to your weight 
management programme.  
Product X is an energy free beverage 
that can help control your weight. 
Conditions of use 
- Meet the relevant annex requirements in HC Regulation 
Comments from Member States 
Could be split in two. 
ID Food or Food constituent Health Relationship Proposed wording 
1277 Carbohydrate foods and 
beverages. 
RECOVERY Enhanced 
muscle glycogen 
Carbohydrate after exercise 
maximises muscle glycogen 
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Clarification provided 
Carbohydrate (including 
glucose, glucose polymers, 
sucrose) in sports nutrition 
products. 
synthesis. 
Enhanced recovery. 
replacement. 
High GI carbohydrate post exercise 
results in higher muscle glycogen 
levels after 24 hours than low GI. 
Liquid carbohydrate is as effective 
as a solid form for glycogen 
resynthesis. 
Replaces glycogen stores used 
during exercise. 
Consumption at frequent intervals 
maintains enhanced muscle 
glycogen synthesis. 
Helps recovery and enhances 
subsequent performance / endurance 
capacity / delayed onset of fatigue. 
Carbohydrate during first hour after 
exercise assures maximal muscle 
glycogen resynthesis rate and speed 
of recovery. 
Clarification provided 
Carbohydrate after exercise 
maximises muscle glycogen 
replacement. High GI carbohydrate 
post exercise results in higher 
muscle glycogen levels after 24 
hours than low GI. Liquid 
carbohydrate is as effective as a 
solid form for glycogen resynthesis. 
Replaces glycogen stores used 
during exercise. Consumption at 
frequent intervals maintains 
enhanced muscle glycogen 
synthesis. Helps recovery and 
enhances subsequent performance / 
endurance capacity / delayed onset 
of fatigue. Carbohydrate during first 
hour after exercise assures maximal 
muscle glycogen resynthesis rate and 
speed of recovery. 
 Conditions of use 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Metabolisable 
carbohydrates: = 65% of total energy (for foods). Metabolisable carbohydrates: = 75% of 
total energy (for beverages). 
ID Food or Food constituent Health Relationship Proposed wording 
1278 Carbohydrate foods and 
beverages. 
Clarification provided 
Claim to be only used for 
Attenuation of the 
perception of effort and 
reduction in pleasure. 
Consumption before and during 
exercise enhances feelings of 
energetic arousal which may impact 
on task persistence and performance. 
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Foods for sportpeople under 
the Dir. 89/398/EEC. 
Metabolisable carbohydrates: 
≥ 65% of total energy (for 
foods). 
At least 75% of total energy 
(for beverages) should be 
derived from metabolisable 
carbohydrate characterized 
by a high glycaemic index 
(examples include glucose, 
glucose polymers, sucrose). 
Suggested use:  
1) 30 to 60g CHO 30 to 60 
minutes before strenuous 
muscular effort. 
2) Minimum 16g, typically 
30 to 60g CHO per hour 
during endurance exercise 
(>50% Vo2 max). 
Reduces the perception of athletic 
fatigue.  
Helps maintain alertness / mood. 
Helps reduce the perception of 
effort, making you feel better during 
exercise. 
A high carbohydrate diet helps to 
reduce feelings of fatigue / perceived 
effort during prolonged exercise. 
Conditions of use 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Metabolisable 
carbohydrates: = 65% of total energy (for foods). Metabolisable carbohydrates: = 75% of 
total energy (for beverages). 
ID Food or Food constituent Health Relationship Proposed wording 
1279 Carbohydrate foods and 
beverages. 
Clarification provided 
Claim to be only used for 
Foods for sportpeople under 
the Dir. 89/398/EEC. 
Metabolisable carbohydrates: 
≥ 65% of total energy (for 
foods). 
At least 75% of total energy 
(for beverages) should be 
derived from metabolisable 
carbohydrate characterized 
by a high glycaemic index 
(examples include glucose, 
glucose polymers, sucrose). 
Suggested use:  
1) 30 to 60g CHO 30 to 60 
minutes before strenuous 
muscular effort. 
2) Minimum 16g, typically 
30 to 60g CHO per hour 
ENDURANCE 
Increased endurance 
capacity;  
Increased endurance 
performance; 
Delayed Fatigue. 
Enhances / maximises glycogen 
stores. 
Carbohydrate before, during 
exercise improves endurance 
performance / perform for longer. 
Carbohydrate rich diets before 
exercise help elevate pre-exercise 
glycogen stores. 
Ingestion during exercise maintains 
blood glucose. 
Glucose is the body’s naturally 
preferred source of energy during 
intense exercise. 
Consumption in events as short as 1 
hr improves exercise performance. 
Endurance capacity / time to 
exhaustion / delays fatigue. 
Carbohydrate loading can delay 
fatigue and benefits endurance and 
multiple sprint sports. 
Energy for endurance / fuel for your 
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during endurance exercise 
(>50% Vo2 max). 
muscles. 
Carbohydrate before and after 
exercise extends endurance time and 
work output more than either alone. 
Glycogen Sparing. 
Ingestion during exercise maintains 
blood glucose. 
Glucose is the body’s naturally 
preferred source of energy during 
intense exercise. 
Conditions of use 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Metabolisable 
carbohydrates: = 65% of total energy (for foods). Metabolisable carbohydrates: = 75% of 
total energy (for beverages). 
ID Food or Food constituent Health Relationship Proposed wording 
1288 Cranberry (Lingonberry) 
juice, (Vaccinium vitis 
idaea, Vaccinium 
macrocarpon). 
Urinary tract. 
Clarification provided 
Contributes to decrease 
adherence of some E. 
coli bacteria in the 
urinary tract walls. 
Cranberry juice helps to keep the 
urinary system in a healthy condition; 
Lingonberry juice has a positive efect 
on the urinary tract; 
Conditions of use 
- Product ready-to-drink (diluted juice, nectar or syrup) containing 9,2 g of juice concentrate; 
used daily over 12 month. 
ID Food or Food constituent Health Relationship Proposed wording 
1370 Name of Food product: Sqeez 
Wild Blueberry Juice Drink 
Description of food in terms of 
food legislation categories: food 
not covered by specific food 
legislation Was food on Irish 
market before 1st July 2007: 
Yes 
Health benefits of food: 
Vision health  
Do benefits relate to a 
disease risk factor: No 
Target group: All of the 
general population including 
children and adults 
Exact wording of claim as it 
appears on product: 
Blueberries have a wide 
range of health benefits 
including anti-ageing 
properties and the 
maintenance of urinary tract 
and vision health  
Is claim a picture: No 
Conditions of use 
- Number of nutrients/other substances that are essential to claimed effect: 1Names of 
nutrient/other substances and Quantity in Average daily serving: 200ml blueberry juice 
Weight of average daily food serving: 200 mililitre(s) Daily amount to be consumed to 
produce claimed effect: 200 mililitre(s)Number of food portions this equates to in everyday 
food portions: 1 Are there factors that could interfere with bioavailability: Yes Please give 
reason: Storage beyond its shelf life Length of time after consumption for claimed effect to 
become apparent: It is apparent immediately Is there a limit to the amount of food which 
should be consumed in order to avoid adverse health effects: No 
Comments from Member States 
Further clarification to support the use of this claim was not submitted to the Food Safety 
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Authority of Ireland 
ID Food or Food constituent Health Relationship Proposed wording 
1514 Combination of millet extract + 
L-cystine + vitamin B5 
(calcium panthothenate) 
Support of hair growth Supports healthy hair growth 
from within. 
Supports the growth of healthy 
hair & nails. 
Supports metabolism of the 
hair roots. 
Conditions of use 
- Dosage: per capsule 140 mg millet extract + 2 mg L-cystine + 9 mg vitamin B5. 2 
capsules/day. 
ID Food or Food component Health Relationship Proposed wording 
1711 Amino acids Stimulate protein 
synthesis. 
To assist in the repair and recovery of 
muscle tissue following strenuous 
exercise. 
Helps muscle maintenance and 
recovery following exercise. 
Conditions of use 
- Claim to be only used for Foods for sportpeople under the Dir. 89/398/EEC. Sports foods 
and food supplements containing protein or amino acids and targetted at sports people 
ID Food or Food constituent Health Relationship Proposed wording 
1952 Green Clay. Digestive health. 
Clarification provided 
Reduce importance of 
gases from intestinal 
fermentations / Increase 
transit time/Decreases 
dyspeptic complaints. 
Helps to support digestion. 
Contributes to digestive comfort. 
Contributes to normal function of the 
gastro-intestinal tract. 
Helps to reduce gastro-intestinal 
discomfort. 
Helps to improve the digestive transit. 
Helps to regulate digestion. 
Contributes to digestive well-being. 
Conditions of use 
- At least 1 g per day. 
- Argile/ Consommation traditionnelle dans le cadre d’une alimentation normale/l'équivalent 
de 720mg/j. 
- 250 mg per day. 
ID Food or Food constituent Health Relationship Proposed wording 
2157 Vitis vinifera (Common 
Name : Grape) 
Vein health 
Clarification provided 
Vein health/ promotes 
venous circulation in the 
Red vine leaf contributes to a good 
blood flow in the legs 
/can reduce the feeling of tired and 
heavy legs/ 
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legs/ 
Beneficially affects the 
venous system/supports 
the venous circulation 
traditionaly used to support skin 
capillatory function/ 
helps to maintain healthy leg-vein 
functions/heavy legs 
Conditions of use 
- owoc, liście, nasiona/ zwykle konsumowane jako tradycyjny artykuł żywnościowy w 
normalnej diecie/ równowartość 5g liścia na dzień. 
- 200 mg Weinblätter–als Extrakt 
- Erwachsene 
- Fruit, leaf, seed / Usual consumption as traditional foodstuff in a normal diet / The 
equivalent of 5 g of leaf per day 
- Traditional use of the leaf 
- Feuille 6x260mg/jour 
- Food component continued: *AS195 Dry leaves/dry extract ratio: 4-6/1 (extraction agent: 
hot water). Characteristic components of the plant extract AS195 are: flavonol-glycosides 
with quercetin-3-O-ß-D-glucuronide (as main flavonoid) and quercetin-3-O-ß-glucoside 
(=isoquercetin). Total flavonol-glycosdes content (HPLC method), calculated as quercetin-
3-O-ß-D-glucuronide, is 3.0-7.0g/100g dry extract. Red Vine Leaf extract AS195 at 360mg 
or 720mg per day. 
ID Food or Food constituent Health Relationship Proposed wording 
2191 Ribes nigrum (Common 
Name: Blackcurrant) 
Muscles and joint health Contributes to the proper functioning 
of muscles and joints / for supple joints 
Conditions of use 
- Leaf / The equivalent of dried leaf as an infusion (20-50 g/litre) 
ID Food or Food constituent Health Relationship Proposed wording 
2556 Maitaké. 
Clarification provided 
Grifola frondosa (Maitake) 
thalle. 
Métabolisme des 
glucides 
Antidiabétique, 
Hypoglycémiant. 
Clarification provided 
Glycemic response: 
maitake possesses 
polysaccharides that 
have an hypoglycemic 
effect. 
Participe au contrôle de la glycémie. 
Aide à maîtriser le taux de sucre. 
Contribue à la régularisation de la 
glycémie. 
Clarification provided 
Helps improve glycemic control / 
helps maintain normal blood sugar 
level. 
Conditions of use 
- Thalle entier 6x200mg/jour. 
ID Food or Food constituent Health Relationship Proposed wording 
2638 blueberry extracts can support maintainig of 
proper night vision 
blueberry can support 
maintainig of proper night 
vision 
Health claims related to not sufficiently characterised foods/food constituents  
 
41 EFSA Journal 2011;9(6):2244 
Conditions of use 
- 18 mg of blueberry extract per day 
ID Food or Food constituent Health Relationship Proposed wording 
2796 Bilberry and anthocyanins from 
blackcurrant 
Eyes The anthocyanins from 
bilberry and mountain 
blackcurrant are good for the 
eyes (improve adaptation to 
the dark and relieve eye 
tiredness caused by computer 
terminal work). 
Conditions of use 
- Wild bilberry contains about 600 mg/100 g of anthocyanins (=anthocyanidine glycosides). 
In clinical studies, a beneficial effect for the eyes has been obtained with a 50-140 mg daily 
dose of anthocyanin. This amount of anthocyanidines is contained in approximately one 
tablespoon of berries. 
- Fruit At least 1900 mg fruit powder per day 
- fruit Infusion : 5-10g of dried fruits per day 
ID Food or Food constituent Health Relationship Proposed wording 
2922 Inulin/oligofructose from 
chicory 
Satiety Inulin/oligofructose help you to feel 
fuller for longer; Foods with 
inulin/oligofructose curb your hunger 
feeling; Foods with 
inulin/oligofructose make you feel 
satisfied 
Conditions of use 
- 16 g/d or 4 g per serving 
Comments from Member States 
identical name is used by claim ID 770 with EFSA comment 0 ? Please explain 
ID Food or Food constituent Health Relationship Proposed wording 
3092 Prebiotics 
Clarification provided 
Prebiotics 
(inulin/oligofructose) 
Digestive health, 
balanced intenstinal 
flora, promotion of 
beneficial flora 
Prebiotics/[name of specific prebiotic] 
- beneficially affects the intestinal 
flora.  
- stimulates growth of the good/ 
beneficial gut flora.  
-positively affects the intestinal health 
Conditions of use 
- Basic criteria: The product shall contain an adequate number of the prebiotic compared to 
the human studies performed. The same daily dose as in the studies should be achievable. 
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GLOSSARY AND ABBREVIATIONS 
FOS  Fructo-oligosaccharides 
GI  Glycaemic index 
HP  High polymerised 
